FilingReader Intelligence
Indegene to integrate AI into drug development and marketing
March 28, 2025 at 01:45 AM UTC•By FilingReader AI
Indegene (BSE: INDGN) is set to host investor and analyst meetings to present its strategy for leveraging generative AI (GenAI) within the life sciences industry. The company is focusing on embedding large language models (LLMs) into business processes to automate key functions in drug development and marketing.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
BSE:INDGN•Bombay Stock Exchange
News Alerts
Get instant email alerts when Indegene publishes news
Free account required • Unsubscribe anytime